Women's Health

Combining Drugs May Improve Ovarian Cancer Survival

Combination treatment saw the most benefit

The research team then took the next step by adding on an immune checkpoint inhibitor as part of the combination treatment. They found that when mice were receiving 5-azacytidine, histone deacetylase inhibitor, and an immune therapy, they got the greatest reduction in ascites and tumor burden, as well as the longest survival. Later experiments with mice with defective immunity helped the researchers discover that it was actually the immune system's action and not the drug's toxicity that was key to eradicating tumor burden.